The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Medicago’s COVID-19 Vaccine Shows Positive Animal Data, Clinical Trial Expected to Wrap Up by November 2021
A COVID-19 vaccine candidate being developed by Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, has yielded positive animal data and is on track to clinical trials, which are expected to start this summer and end by November next year.…
To read the full story
Related Article
- Medicago Inks COVID-19 Vaccine Deal with Canadian Govt
October 27, 2020
- Medicago Begins PI Trial of COVID-19 Vaccine in Canada
July 16, 2020
- Medicago, GSK Team Up to Develop Adjuvanted COVID-19 Vaccine, PI to Commence in Mid-July
July 9, 2020
- Medicago Successfully Produces COVID-19 Vaccine Candidate
March 13, 2020
BUSINESS
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Servier Japan Seeks First-Line Pancreatic Cancer Use for Onivyde
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…